Published: May 12, 2021
CAMBRIDGE, Mass. and SHANGHAI, May 12, 2021 /PRNewswire/ Citrine Medicine, a China-based rare disease therapeutics company, today announced that it has signed a licensing agreement with Diurnal Group plc (AIM: DNL), a specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases. The deal provides Citrine with exclusive rights to develop and commercialize Efmody
® (hydrocortisone modified-release hard capsules – development name Chronocort
®) in the Greater China market. In January, Citrine signed a licensing agreement with Dirunal Group for Alkindi,
® the first preparation of hydrocortisone specifically designed for use in children suffering from pediatric adrenal insufficiency (AI) and congenital adrenal hyperplasia (CAH).
/PRNewswire/ Citrine Medicine, a China-based rare disease therapeutics company, today announced that it has signed a licensing agreement with Diurnal Group.
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
News provided by
Share this article
SHANGHAI, Jan. 9, 2021 /PRNewswire/
VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China, announced today the closing of a $150 million Series B financing.
The round was led by Sequoia China with participation from OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commer
Share this article
Share this article
CAMBRIDGE, Mass. and SUZHOU, China, Jan. 7, 2021 /PRNewswire/ Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the first closing of an oversubscribed $53.5 million Series B+ financing. The financing was co-led by RA Capital Management and Vivo Capital, with participation from Foresite Capital and APlus Partners. Existing investors, including Quan Capital and Qiming Venture Partners USA, also participated in the first closing. While the complement system has historically been difficult to target given its complexity, we believe our LOGIC drug discovery platform enables us to approach complement mediation in new and different ways, unlocking transformative therapies for patients, said Frederick Beddingfield, MD, PhD, Chief Executive Officer of Kira Pharmaceuticals. We are honored to have the support of top-tier global invest